LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement

Based on its evaluation, NICE concludes that the sutureless aortic valve replacement procedure may be faster than the standard procedure, reducing cardiopulmonary and aortic cross-clamp times. Additionally, sufficient evidence was found to support the safety and efficacy of the sutureless procedure. The guidance was informed by a comprehensive assessment of literature and detailed review of evidence from various sources, including six systematic reviews and meta-analyses and two case series. The review also included patient feedback and considered outcomes such as quality of life, valve durability and clinical improvements.

Concurrently, LivaNova completed enrollment for the Perceval^® Sutureless Implant vs. Standard Aortic Valve Replacement (PERSIST-AVR) study with more than 900 patients from 47 centers in 12 countries. While the original study protocol was for 1,234 patients, the introduction of an innovative adaptive design allowed for a reduced sample size and the ability to analyze data earlier. PERSIST-AVR, which began in April 2016, is the only worldwide, prospective, randomized, multi-center trial comparing the LivaNova Perceval sutureless aortic valve with standard sutured bioprostheses in patients with aortic valve disease.

The principal investigators for PERSIST-AVR are Professor Theodor Fischlein, M.D., Ph.D., Paracelsus Medical University Cardiovascular Center, Nuremberg, Germany, and Professor Roberto Lorusso, M.D., Ph.D., Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands. “The speed of recruitment and global engagement is a solid statement for the adoption of Perceval around the world,” said Fischlein. Lorusso added, “This release of data will certainly support our daily experience of aortic valve replacement with Perceval.”

Since 2007, Perceval has been implanted in thousands of patients with aortic valve disease to help improve their lives.

“Our Perceval sutureless aortic valve is one of our important growth drivers and continues to offer surgeons and patients a proven alternative with unique benefits compared to traditional aortic valve replacement,” said Alistair Simpson, LivaNova General Manager of Cardiac Surgery. “The updated NICE guidance and completion of our PERSIST-AVR clinical trial enrollment are key milestones that will support an even greater adoption rate.”

For more information on the NICE guidance, visit https://www.nice.org.uk/guidance/ipg624.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.

For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control. You should carefully consider the risks and uncertainties that affect LivaNova, including those described in the “Risk Factors” section of LivaNova’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission.

All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.